Page last updated: 2024-11-06

sorbitol and Body Weight

sorbitol has been researched along with Body Weight in 110 studies

D-glucitol : The D-enantiomer of glucitol (also known as D-sorbitol).

Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.

Research Excerpts

ExcerptRelevanceReference
"This study examined the effects of hyperglycemia and treatment with the aldose reductase inhibitor, Tolrestat, on the pain behavior evoked by injection of formalin into the dorsum of a single hind paw."7.69Tolrestat treatment prevents modification of the formalin test model of prolonged pain in hyperglycemic rats. ( Calcutt, NA; Malmberg, AB; Yaksh, TL; Yamamoto, T, 1994)
" However, low peroral bioavailability is a major limiting factor for the success of clinical utilization of curcumin."5.39Efficacy of biodegradable curcumin nanoparticles in delaying cataract in diabetic rat model. ( Balakrishna, N; Grama, CN; Kumar, MN; Patil, MA; Raghu, G; Reddy, GB; Suryanarayana, P, 2013)
" One of these toxic findings was cataract, and we have found that cataract appeared in rats dosed orally with FK506 for 13 weeks and more."5.30Cataract development induced by repeated oral dosing with FK506 (tacrolimus) in adult rats. ( Fukuhara, Y; Hisatomi, A; Ishida, H; Mitamura, T; Murato, K; Ohara, K; Takahashi, Y, 1997)
" This study intends to examine the effects of sea buckthorn and metformin on body weight, water and feed intake, glycaemia, insulinemia, sorbitol accumulation and cataract development in Zucker diabetic fatty rats, which represent an animal model of type 2 Diabetes mellitus, as well as to characterize the individual content of bioactive substances and the antioxidant activity of sea buckthorn."4.12The consumption of sea buckthorn (Hippophae rhamnoides L.) effectively alleviates type 2 diabetes symptoms in spontaneous diabetic rats. ( Brindza, J; Capcarova, M; Dupak, R; Hrnkova, J; Ivanisova, E; Kalafova, A; Kovac, J; Prnova, MS; Schneidgenova, M; Simonova, N; Tokarova, K, 2022)
"Biorhythms with higher levels of activity of sorbitol dehydrogenase and lactate dehydrogenase in blood plasma, specific activity of sorbitol dehydrogenase, lactate dehydrogenase, and malate dehydrogenase in the liver, and body weight of rats were more pronounced in the spring-summer period than in the autumn-winter period."3.74Biorhythms of activities of liver and blood dehydrogenases and changes in body weight of the rats feeding normal diet or excess of sugar substitutes. ( Kichenko, SM; Petrovich, YA; Volozhin, AI; Zubtsov, VA, 2007)
"Studies show that the pyruvate treatment decreased the extent of several biochemical changes known to be associated with cataract formation, such as the elevation in the levels of glycated proteins, sorbitol, lipid peroxidation (MDA) and inhibition of the cation pump."3.70Diabetes-induced biochemical changes in rat lens: attenuation of cataractogenesis by pyruvate. ( Ali, AH; Devamanoharan, PS; Henein, M; Varma, SD; Zhao, W, 2000)
"This study examined the effects of hyperglycemia and treatment with the aldose reductase inhibitor, Tolrestat, on the pain behavior evoked by injection of formalin into the dorsum of a single hind paw."3.69Tolrestat treatment prevents modification of the formalin test model of prolonged pain in hyperglycemic rats. ( Calcutt, NA; Malmberg, AB; Yaksh, TL; Yamamoto, T, 1994)
" The primary objective was to examine the dose-response relationship of licogliflozin treatment in body weight reduction relative to placebo at 12 weeks."2.94Dose-dependent reduction in body weight with LIK066 (licogliflozin) treatment in Japanese patients with obesity. ( Keefe, D; Sano, M; Tsumiyama, I; Yokote, K, 2020)
"This dose-response analysis evaluated change in body weight following 24 weeks with four once-daily and twice-daily licogliflozin doses (2."2.94Licogliflozin, a Novel SGLT1 and 2 Inhibitor: Body Weight Effects in a Randomized Trial in Adults with Overweight or Obesity. ( Bays, HE; Keefe, D; Kozlovski, P; Proot, P; Shao, Q, 2020)
" Safety assessments included adverse events, laboratory tests and vital signs."2.87Efficacy and safety of luseogliflozin added to insulin therapy in Japanese patients with type 2 diabetes: a multicenter, 52-week, clinical study with a 16-week, double-blind period and a 36-week, open-label period. ( Fukatsu, A; Imazeki, H; Ochiai, H; Sakai, S; Sasaki, T; Seino, Y, 2018)
" The safety end points included adverse events (AEs) and laboratory parameters."2.82Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus. ( Fukatsu, A; Haneda, M; Inagaki, N; Kakiuchi, H; Kaku, K; Sakai, S; Samukawa, Y; Sasaki, T; Sato, Y; Seino, Y, 2016)
"Although patients with type 2 diabetes often have hepatic impairment, few reports have been published concerning the influence of luseogliflozin on HbA1c and hepatic function in patients with type 2 diabetes accompanied by hepatic impairment."2.82Luseogliflozin, A Sodium Glucose Co-transporter 2 Inhibitor, Alleviates Hepatic Impairment in Japanese Patients with Type 2 Diabetes. ( Kusunoki, M; Miyata, T; Natsume, Y; Oshida, Y; Sato, D; Suga, T; Tsutsui, H; Tsutsumi, K, 2016)
"In posthaemorrhagic and postmeningitic hydrocephalus valuable time was gained before shunt therapy until the infant and his CSF were fit for operation."2.64Isosorbide in treatment of infantile hydrocephalus. ( Lorber, J, 1975)
" These include the question as to when and to whom early use of SGLT2 inhibitors would be most suitable, as well as instructions on reduction of sulfonylurea dosage during add-on treatment."1.42Luseogliflozin and other sodium-glucose cotransporter 2 inhibitors: no enemy but time? ( Pafili, K; Papanas, N, 2015)
" However, low peroral bioavailability is a major limiting factor for the success of clinical utilization of curcumin."1.39Efficacy of biodegradable curcumin nanoparticles in delaying cataract in diabetic rat model. ( Balakrishna, N; Grama, CN; Kumar, MN; Patil, MA; Raghu, G; Reddy, GB; Suryanarayana, P, 2013)
"Fidarestat inhibited the increase with an IC50 value of 18 nmol/l."1.31Pharmacological properties of fidarestat, a potent aldose reductase inhibitor, clarified by using sorbitol in human and rat erythrocytes. ( Aoki, T; Makino, M; Mizuno, K; Sassa, H; Sobajima, H; Suzuki, T; Taniko, K, 2001)
"After 6 weeks of untreated streptozotocin diabetes, rats were treated for 2 weeks."1.30Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats. ( Basso, M; Cameron, NE; Cotter, MA; Hohman, TC, 1997)
" One of these toxic findings was cataract, and we have found that cataract appeared in rats dosed orally with FK506 for 13 weeks and more."1.30Cataract development induced by repeated oral dosing with FK506 (tacrolimus) in adult rats. ( Fukuhara, Y; Hisatomi, A; Ishida, H; Mitamura, T; Murato, K; Ohara, K; Takahashi, Y, 1997)
"Methylguanidine was only approximately 7% as effective as aminoguanidine as an inhibitor of AGE formation from L-lysine and G6P; both compounds were poor inhibitors of AR."1.29Prevention of diabetic vascular dysfunction by guanidines. Inhibition of nitric oxide synthase versus advanced glycation end-product formation. ( Chang, K; Corbett, JA; Currie, MG; Hasan, KS; McDaniel, ML; Misko, TP; Moore, WM; Petrash, JM; Smith, SR; Tilton, RG, 1993)
"At 8 months galactosemia reduced NCV to 58% of control values, while ARI-treatment for 8 months improved NCV to 71% of control values."1.29Galactosemia produces ARI-preventable nodal changes similar to those of diabetic neuropathy. ( Basso, M; Cherian, PV; Hohman, TC; Kamijo, M; Sima, AA, 1994)
"Iloprost was administered intraperitoneally to streptozotocin-induced diabetic rats at a dose of 10 micrograms/kg/day for a month."1.28Effect of a prostaglandin I2 derivative (iloprost) on peripheral neuropathy of diabetic rats. ( Ito, H; Kanazawa, A; Miwa, T; Ohno, A; Tanaka, A, 1992)
"The betaine increase compensated for the sorbitol decrease such that the total organic osmolytes maintained the same ratio to sodium contents as controls."1.28Effects on rat renal osmolytes of extended treatment with an aldose reductase inhibitor. ( Edmands, S; Yancey, PH, 1992)
"The results suggest overall that while riboflavin deficiency may affect certain biochemical indices, such as sorbitol and thiobarbituric-reactive substances, in the lens and other tissues, these changes are not the result of lowered glutathione levels."1.28Glutathione and related indices in rat lenses, liver and red cells during riboflavin deficiency and its correction. ( Bates, CJ, 1991)
"If not treated, visceral leishmaniasis is often fatal."1.28Chemotherapy of experimental visceral leishmaniasis in the opossum. ( Chapman, WL; Hanson, WL; White, MR, 1989)

Research

Studies (110)

TimeframeStudies, this research(%)All Research%
pre-199044 (40.00)18.7374
1990's40 (36.36)18.2507
2000's13 (11.82)29.6817
2010's9 (8.18)24.3611
2020's4 (3.64)2.80

Authors

AuthorsStudies
Dupak, R1
Hrnkova, J1
Simonova, N1
Kovac, J1
Ivanisova, E1
Kalafova, A1
Schneidgenova, M1
Prnova, MS1
Brindza, J1
Tokarova, K1
Capcarova, M1
Yokote, K1
Sano, M1
Tsumiyama, I1
Keefe, D2
Bays, HE1
Kozlovski, P1
Shao, Q1
Proot, P1
Jinnouchi, H1
Yoshida, A1
Tsuyuno, H1
Iwamoto, K1
Sugiyama, S1
Hieshima, K1
Kajiwara, K1
Kurinami, N1
Suzuki, T4
Jinnouchi, K1
Jinnouchi, T1
Seino, Y3
Sasaki, T3
Fukatsu, A3
Imazeki, H1
Ochiai, H1
Sakai, S3
Kojima, N1
Williams, JM1
Takahashi, T1
Miyata, N1
Roman, RJ1
Sakamaki, S1
Kawanishi, E1
Koga, Y1
Yamamoto, Y1
Kuriyama, C1
Matsushita, Y1
Ueta, K1
Nomura, S1
Grama, CN1
Suryanarayana, P1
Patil, MA1
Raghu, G1
Balakrishna, N1
Kumar, MN1
Reddy, GB1
Pafili, K1
Papanas, N1
Kaku, K2
Inagaki, N2
Haneda, M2
Ubukata, M1
Samukawa, Y2
Kakiuchi, H1
Sato, Y1
Kusunoki, M1
Natsume, Y1
Sato, D1
Tsutsui, H1
Miyata, T1
Tsutsumi, K1
Suga, T1
Oshida, Y1
Li, X1
Hu, J1
Zhang, R1
Sun, X1
Zhang, Q1
Guan, X1
Chen, J1
Zhu, Q1
Li, S1
Petrovich, YA1
Volozhin, AI1
Zubtsov, VA1
Kichenko, SM1
Cheng, X1
Ni, B1
Zhang, Z1
Liu, Q1
Wang, L1
Ding, Y1
Hu, Y1
VANHEYNINGEN, R1
HOEGBERG, KG1
LINDVALL, S1
BRIN, M1
Jones, LD1
Castleberry, MW1
Canham, JE1
King, NW1
Yokozawa, T1
Yamabe, N1
Cho, EJ1
Nakagawa, T1
Oowada, S1
Li, F1
Szabó, C1
Pacher, P1
Southan, GJ1
Abatan, OI1
Charniauskaya, T1
Stevens, MJ3
Obrosova, IG2
Bernobich, E1
Cosenzi, A1
Campa, C1
Zennaro, C1
Sasso, F1
Paoletti, S1
Bellini, G1
Shimada, H2
Takahashi, M1
Shimada, A1
Okawara, T1
Yasutake, A1
Imamura, Y1
Kiyozumi, M2
Yono, M1
Latifpour, J1
Yoshida, M3
Ueda, S1
Lin, HJ1
Loh, CH1
Liao, MT1
Liu, TT1
Hsieh, PS1
Frostell, G1
Keyes, PH1
Larson, RH1
Bonfiglioli, D1
Sommariva, D1
Rovelli, L1
Panigo, F1
Gatti, P1
Cialfi, A1
Grimoldi, M1
Cabrini, E1
Fasoli, A1
Grenby, TH1
Colley, J1
Bauchart, D2
Gillon, KR1
Hawthorne, JN1
Siegel, EG1
Trapp, VE1
Wollheim, CB1
Renold, AE1
Schmidt, FH1
Bauer, KD1
Griminger, P1
Hotta, N5
Kakuta, H3
Fukasawa, H3
Koh, N5
Sakakibara, F5
Nakamura, J5
Hamada, Y4
Wakao, T2
Hara, T5
Mori, K3
Tilton, RG2
Chang, K2
Hasan, KS1
Smith, SR1
Petrash, JM1
Misko, TP1
Moore, WM1
Currie, MG1
Corbett, JA1
McDaniel, ML1
Tesfamariam, B1
Palacino, JJ1
Weisbrod, RM1
Cohen, RA1
Soulis-Liparota, T1
Cooper, ME1
Dunlop, M1
Jerums, G1
Kamijo, M2
Basso, M2
Cherian, PV1
Hohman, TC3
Sima, AA2
Calcutt, NA2
Malmberg, AB1
Yamamoto, T1
Yaksh, TL1
Yee, S1
Fazekas-May, M1
Walker, EM1
Montague, D1
Stern, S1
Heard, KW1
Klein, P1
Reingruber, B1
Lattimer, SA1
Van Huysen, C2
Greene, DA2
Hidaka, S2
Funakoshi, T1
Tsuruoka, M2
Kojima, S2
Hamara, Y1
Nakashima, E3
Sasaki, H2
Sakamoto, N2
Cameron, NE3
Cotter, MA3
Naruse, K1
Terril-Robb, LA1
Clemons, DJ1
Besch-Williford, C1
O'Brien, DP1
O'Dell, BL1
Ashizawa, N2
Sugiyama, Y2
Akaike, N2
Ohbayashi, S2
Aotsuka, T2
Abe, N1
Fukushima, K1
Matsuura, A2
Ishida, H1
Mitamura, T1
Takahashi, Y1
Hisatomi, A1
Fukuhara, Y1
Murato, K1
Ohara, K1
Kasama, N1
Inukai, S1
Shinohara, R1
Mano, T1
Nagasaka, A1
Sawai, Y1
Uchimura, K1
Hayashi, R1
Hayakawa, N1
Nagata, M1
Makino, M3
Kakizawa, H1
Itoh, Y1
Nakai, A1
Itoh, M1
Pieper, GM1
Lai, CS1
Fathallah, L1
Cao, X1
Kato, N2
Mizuno, K3
Yagihashi, S1
Zhao, W1
Devamanoharan, PS1
Henein, M1
Ali, AH1
Varma, SD1
Sobajima, H1
Aoki, T1
Sassa, H1
Taniko, K1
Coppey, LJ1
Gellett, JS1
Davidson, EP1
Dunlap, JA1
Lund, DD1
Salvemini, D1
Yorek, MA1
Carlson, GP1
Tiscornia, OM1
Lorber, J1
Ohno, A1
Kanazawa, A1
Tanaka, A1
Miwa, T1
Ito, H1
Matsubara, A1
Nakano, K1
Kurono, M1
Bannai, C1
Yamazaki, M1
Matsushima, Y1
Kunika, K1
Itakura, M1
Okuda, Y1
Yamashita, K1
Edmands, S1
Yancey, PH1
Schmolke, M1
Schleicher, E1
Guder, WG1
Bates, CJ2
Cowen, TD1
Evans, PH1
Cikrt, M1
Bláha, K1
Nerudová, J1
Bittnerová, D1
Jehlicková, H1
Jones, MM2
Sonobe, M2
Yasuda, H2
Hisanaga, T1
Maeda, K1
Yamashita, M2
Kawabata, T1
Kikkawa, R2
Taniguchi, Y1
Shigeta, Y2
Carrington, AL1
Ettlinger, CB1
Tomlinson, DR3
Sredy, J1
Flam, BR1
Sawicki, DR1
Kargacin, B1
Blanusa, M1
Arezina, R1
Kostial, K1
Singh, PK1
Jones, M1
Kumari, K1
Murthy, PS1
Sahib, MK1
Inoue, T1
Miwa, I1
Hirano, M1
Kanbara, M1
Okuda, J1
Suzuki, K1
Yen-Chung, H1
Toyota, T1
Goto, Y1
Hirata, Y1
Okada, K1
Fields, M1
Lewis, CG1
Beal, T1
Scholfield, D1
Mayer, JH1
Willars, GB1
Townsend, J1
Compton, AM1
Churchill, RD1
Craven, PA1
DeRubertis, FR1
Gaynes, BI1
Watkins, JB1
White, MR1
Chapman, WL1
Hanson, WL1
Sochor, M1
Kunjara, S1
McLean, P1
Kemper, C1
Dvornik, D1
Williamson, JR1
Prater, C1
Jeffrey, JR1
Weigel, C1
Sherman, WR1
Eades, DM1
Kilo, C2
Yano, M1
Hashimoto, F1
Sato, M1
Ohboshi, C1
Hirota, M1
Oshima, I1
Ohe, Y1
Shin, S1
Shima, K1
Hatanaka, I1
Terada, M1
Gale, GR1
Atkins, LM1
Smith, AB1
Jones, SG1
Basinger, MA1
Sussman, I1
Matschinsky, FM1
Hämäläinen, MM1
Potezny, N1
McClure, J1
Rofe, AM1
Conyers, RA1
MacKenzie, KM1
Hauck, WN1
Wheeler, AG1
Roe, FJ1
Aurousseau, B1
Auclair, E1
Rowland, N1
Meile, MJ1
Nicolaïdis, S1
Principi, N1
Reali, E1
Rivolta, A1
Elebute, EA1
Hillbom, ME4
Förster, H1
Hoffmann, H1
Hoos, I1
Spivey, J1
Johnston, ID1
Alfin-Slater, RB1
Wells, P1
Aftergood, L1
Melnick, D1
Pikkarainen, PH2
Jonás, P1
Ciger, J1
Havris, S1
Wagner, KH1
Wagner-Hering, E1
Shehadeh, Z1
Grantham, RN1
Brecher, GA1
Jacobson, ED1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized, Double-blind, Dose-finding Study to Evaluate the Change in Weight After 12 Weeks Treatment With 4 Doses of LIK066 Compared to Placebo in Japanese Patients With Obesity Disease[NCT03320941]Phase 2126 participants (Actual)Interventional2017-12-07Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Percentage Change From Baseline in Body Weight at Week 12

The dose-response relationship of LIK066 as measured by percent change from baseline in body weight relative to placebo after 12 weeks of treatment. (NCT03320941)
Timeframe: Baseline, Week 12

InterventionPercent Change (Number)
LIK066 2.5mg qd-1.86
LIK066 10mg qd-2.84
LIK066 25 mg qd-3.41
LIK066 50 mg qd-3.80
Placebo0.11

Pharmacokinetics - Plasma Trough Concentrations of LIK066

Plasma trough concentrations of LIK066 were measured at Week 12 after daily administrations of LIK066 (2.5, 10, 25 and 50 mg). (NCT03320941)
Timeframe: Week 12

Interventionng/mL (Mean)
LIK066 2.5mg qd1.63
LIK066 10mg qd4.17
LIK066 25 mg qd12.8
LIK066 50 mg qd26.4

Change From Baseline at Week 12 on Diastolic Blood Pressure (DBP)

After the subject has been sitting for 5 minutes with the back supported and both feet placed on the floor, DBP will be measured three times using the automatic BP monitor and an appropriate size cuff. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12

,,,,
InterventionmmHg (Mean)
Overall StudyDysglycemicT2DM
LIK066 10mg qd-3.54-4.40-2.45
LIK066 2.5mg qd-3.72-3.32-4.00
LIK066 25 mg qd-4.36-2.46-5.98
LIK066 50 mg qd-5.23-4.25-5.92
Placebo-3.12-4.31-1.93

Change From Baseline at Week 12 on Fasting Plasma Glucose (FPG)

FPG will be measured from a blood sample obtained after an overnight fast (at least 8h after last evening food intake) at a central laboratory. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12

,,,,
Interventionmmol/L (Mean)
Overall StudyDysglycemicT2DM
LIK066 10mg qd-0.665-0.126-1.111
LIK066 2.5mg qd-0.3340.002-0.606
LIK066 25 mg qd-0.747-0.262-1.145
LIK066 50 mg qd-0.986-0.472-1.377
Placebo-0.160-0.217-0.079

Change From Baseline at Week 12 on Systolic Blood Pressure (SBP)

After the subject has been sitting for 5 minutes with the back supported and both feet placed on the floor, SBP will be measured three times using the automatic BP monitor and an appropriate size cuff. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12

,,,,
InterventionmmHg (Mean)
Overall StudyDysglycemicT2DM
LIK066 10mg qd-5.12-7.10-2.96
LIK066 2.5mg qd-4.90-5.79-4.16
LIK066 25 mg qd-6.36-3.58-8.63
LIK066 50 mg qd-6.94-4.17-9.00
Placebo-5.36-7.09-3.77

Change From Baseline at Week 12 on Waist Circumference at Umbilical Level

Waist circumference will be measured to the nearest 0.1 cm in a standing position, at the end of a normal expiration, using a tape at the level of umbilicus. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12

,,,,
Interventioncm (Mean)
Overall StudyDysglycemicT2DM
LIK066 10mg qd-2.63-4.49-1.39
LIK066 2.5mg qd-2.47-2.78-2.22
LIK066 25 mg qd-2.65-2.08-2.90
LIK066 50 mg qd-3.11-2.23-3.88
Placebo-1.37-0.41-2.19

Change From Baseline in Uric Acid at Week 12

Uric acid will be measured from a blood sample and analyzed at a central laboratory. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12

,,,,
Interventionμmol/L (Mean)
Overall StudyDysglycemicT2DM
LIK066 10mg qd-55.2-74.0-39.7
LIK066 2.5mg qd-52.6-74.9-34.1
LIK066 25 mg qd-58.4-69.1-48.4
LIK066 50 mg qd-62.0-72.9-51.6
Placebo12.412.013.4

Change From Baseline on Urine Albumin at Week 12

Urine albumin will be measured from urine sample and analyzed at a central laboratory. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12

,,,,
Interventionx 10^4 mmol/L (Mean)
Overall StudyDysglycemicT2DM
LIK066 10mg qd0.0082.030-1.051
LIK066 2.5mg qd-1.838-1.941-3.899
LIK066 25 mg qd-3.902-2.456-3.605
LIK066 50 mg qd-3.099-3.406-2.165
Placebo-1.282-3.611-0.174

Change From Baseline on Urine Albumin to Creatinine Ratio at Week 12

Urine albumin to creatinine ratio will be measured from urine sample and analyzed at a central laboratory. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12

,,,,
Interventionmg/mmol (Mean)
Overall StudyDysglycemicT2DM
LIK066 10mg qd-0.8480.487-1.863
LIK066 2.5mg qd-0.849-0.553-1.234
LIK066 25 mg qd-2.552-0.771-4.005
LIK066 50 mg qd-1.878-1.018-2.631
Placebo-1.504-1.122-1.839

Percent Change From Baseline at Week 12 on High Sensitive C-reactive Protein (hsCRP)

High sensitivity CRP will be measured from a blood sample and analyzed at a central laboratory. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12

,,,,
InterventionPercentage (Mean)
Overall StudyDysglycemicT2DM
LIK066 10mg qd69.0046.593113.169
LIK066 2.5mg qd-48.44816.582-89.337
LIK066 25 mg qd-24.207-36.745-18.143
LIK066 50 mg qd-55.536-43.562-71.025
Placebo-93.268-6.298-174.159

Percent Change From Baseline on Subcutaneous Fat Area (SFA) at Week 12

SFA by CT scan will be measured at visits and evaluated centrally. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12

,,,,
InterventionPercentage (Mean)
Overall StudyDysglycemicT2DM
LIK066 10mg qd-4.454-5.962-3.646
LIK066 2.5mg qd-6.562-7.745-5.457
LIK066 25 mg qd-7.983-7.234-8.415
LIK066 50 mg qd-5.745-2.127-8.481
Placebo-3.477-4.328-2.821

Percent Change From Baseline on Visceral Fat Area (VFA) at Week 12

VFA by CT scan will be measured at visits and evaluated centrally. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12

,,,,
InterventionPercent (Mean)
Overall StudyDysglycemicT2DM
LIK066 10mg qd-5.832-6.438-5.934
LIK066 2.5mg qd-4.139-1.532-6.461
LIK066 25 mg qd-9.185-5.977-12.916
LIK066 50 mg qd-11.352-7.333-14.728
Placebo-3.949-0.390-7.137

Percentage Change From Baseline at Week 12 on Fasting Lipid Profile - High Density Lipoprotein (HDL)

Fasting lipid profile (HDL), will be measured on blood samples obtained after an overnight fast and analyzed at a central laboratory For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12

,,,,
InterventionPercentage (Mean)
Overall StudyDysglycemicT2DM
LIK066 10mg qd-2.4610.329-4.696
LIK066 2.5mg qd1.499-0.5192.886
LIK066 25 mg qd-5.253-3.279-6.993
LIK066 50 mg qd0.112-0.1470.235
Placebo-3.454-4.329-2.677

Percentage Change From Baseline at Week 12 on Fasting Lipid Profile - Low Density Lipoprotein (LDL)

Fasting lipid profile (LDL), will be measured on blood samples obtained after an overnight fast and analyzed at a central laboratory For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12

,,,,
InterventionPercentage (Mean)
Overall StudyDysglycemicT2DM
LIK066 10mg qd-2.363-4.473-1.562
LIK066 2.5mg qd0.757-3.0653.727
LIK066 25 mg qd0.0372.579-1.295
LIK066 50 mg qd4.7262.1286.803
Placebo-0.552-3.9942.942

Percentage Change From Baseline at Week 12 on Fasting Lipid Profile - Total Cholesterol

Fasting lipid profile (total cholesterol), will be measured on blood samples obtained after an overnight fast and analyzed at a central laboratory For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12

,,,,
InterventionPercentage (Mean)
Overall StudyDysglycemicT2DM
LIK066 10mg qd-2.983-6.017-1.367
LIK066 2.5mg qd-1.290-3.0550.158
LIK066 25 mg qd0.8844.273-1.646
LIK066 50 mg qd0.302-1.7341.817
Placebo-2.244-3.559-0.671

Percentage Change From Baseline at Week 12 on Fasting Lipid Profile - Triglycerides (TG)

Fasting lipid profile (Triglycerides (TG)), will be measured on blood samples obtained after an overnight fast and analyzed at a central laboratory For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12

,,,,
InterventionPercentage (Mean)
Overall StudyDysglycemicT2DM
LIK066 10mg qd11.057-1.98623.108
LIK066 2.5mg qd1.840-1.1531.016
LIK066 25 mg qd43.92852.28434.747
LIK066 50 mg qd5.30714.061-0.057
Placebo17.40120.96213.806

Percentage Change From Baseline at Week 12 on Hemoglobin A1c (HbA1c)

HbA1c will be measured from a blood sample obtained and analyzed at a central laboratory. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12

,,,,
InterventionPercentage (Mean)
Overall StudyDysglycemicT2DM
LIK066 10mg qd-0.355-0.184-0.491
LIK066 2.5mg qd-0.285-0.139-0.405
LIK066 25 mg qd-0.366-0.196-0.502
LIK066 50 mg qd-0.418-0.163-0.618
Placebo-0.079-0.050-0.093

Percentage Change From Baseline in Body Weight at Week 12 in Dysglycemic Participants and Participants With Type 2 Diabetes Mellitus (T2DM)

The dose-response relationship for weight loss in dysglycemic participants and participants with T2DM. Percentage change from baseline in body weight at Week 12. (NCT03320941)
Timeframe: Baseline, Week 12

,,,,
Interventionpercentage change (Number)
DysglycemicT2DM
LIK066 10mg qd-2.95-2.66
LIK066 2.5mg qd-1.90-1.64
LIK066 25 mg qd-3.29-3.42
LIK066 50 mg qd-3.47-4.23
Placebo0.000.10

Responder Rates According to Percentage Decrease in Body Weight From Baseline to Week 12

The responder rates according to percentage decrease in body weight either ≥ 3%, ≥ 5% or ≥ 10%, from baseline at Week 12, for the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 No Statistical Analysis for >=5% and >=10% was not calculated due to division by zero (NCT03320941)
Timeframe: Baseline, Week 12

,,,,
InterventionPercentage of Participants (Number)
>= 3%>= 5%>= 10%>= 3% (Dysglycemic)>= 5% (Dysglycemic)>= 10% (Dysglycemic)>= 3% (T2DM)>= 5% (T2DM)>= 10% (T2DM)
LIK066 10mg qd55.627.80.075.062.50.040.00.000.00
LIK066 2.5mg qd15.85.30.012.50.00.018.29.10.00
LIK066 25 mg qd50.017.90.038.523.10.060.013.30.00
LIK066 50 mg qd56.726.73.346.223.10.064.729.45.9
Placebo7.10.00.07.70.00.06.70.000.00

Reviews

1 review available for sorbitol and Body Weight

ArticleYear
Value of glucose control in preventing complications of diabetes.
    The American journal of medicine, 1985, Aug-23, Volume: 79, Issue:2B

    Topics: Adult; Animals; Blood Glucose; Blood Pressure; Blood Vessels; Body Weight; Collagen; Diabetes Compli

1985

Trials

7 trials available for sorbitol and Body Weight

ArticleYear
Dose-dependent reduction in body weight with LIK066 (licogliflozin) treatment in Japanese patients with obesity.
    Diabetes, obesity & metabolism, 2020, Volume: 22, Issue:7

    Topics: Adult; Anhydrides; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Human

2020
Licogliflozin, a Novel SGLT1 and 2 Inhibitor: Body Weight Effects in a Randomized Trial in Adults with Overweight or Obesity.
    Obesity (Silver Spring, Md.), 2020, Volume: 28, Issue:5

    Topics: Adolescent; Adult; Aged; Anhydrides; Body Weight; Double-Blind Method; Female; Humans; Male; Middle

2020
Efficacy and safety of luseogliflozin added to insulin therapy in Japanese patients with type 2 diabetes: a multicenter, 52-week, clinical study with a 16-week, double-blind period and a 36-week, open-label period.
    Current medical research and opinion, 2018, Volume: 34, Issue:6

    Topics: Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Comb

2018
Fifty-two-week long-term clinical study of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.
    Endocrine journal, 2015, Volume: 62, Issue:7

    Topics: Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hy

2015
Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus.
    Clinical therapeutics, 2016, Jan-01, Volume: 38, Issue:1

    Topics: Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Admini

2016
Luseogliflozin, A Sodium Glucose Co-transporter 2 Inhibitor, Alleviates Hepatic Impairment in Japanese Patients with Type 2 Diabetes.
    Drug research, 2016, Volume: 66, Issue:11

    Topics: Asian People; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Hu

2016
Isosorbide in treatment of infantile hydrocephalus.
    Archives of disease in childhood, 1975, Volume: 50, Issue:6

    Topics: Adolescent; Body Weight; Cerebrospinal Fluid Shunts; Clinical Trials as Topic; Diarrhea; Female; Hum

1975

Other Studies

102 other studies available for sorbitol and Body Weight

ArticleYear
The consumption of sea buckthorn (Hippophae rhamnoides L.) effectively alleviates type 2 diabetes symptoms in spontaneous diabetic rats.
    Research in veterinary science, 2022, Dec-20, Volume: 152

    Topics: Animals; Antioxidants; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Frui

2022
Changes in urinary glucose concentration and body weight in patients treated with the selective SGLT2 inhibitor luseogliflozin.
    Diabetes research and clinical practice, 2021, Volume: 182

    Topics: Blood Glucose; Blood Glucose Self-Monitoring; Body Weight; Diabetes Mellitus, Type 2; Glucose; Human

2021
Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats.
    The Journal of pharmacology and experimental therapeutics, 2013, Volume: 345, Issue:3

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Glucose; Blood Pressure; Body Weight; Diabe

2013
Synthesis and biological evaluation of thiophene-C-glucosides as sodium-dependent glucose cotransporter 2 inhibitors.
    Chemical & pharmaceutical bulletin, 2013, Volume: 61, Issue:10

    Topics: Animals; Body Weight; CHO Cells; Cricetinae; Cricetulus; Glucose; Glucosides; Humans; Hypoglycemic A

2013
Efficacy of biodegradable curcumin nanoparticles in delaying cataract in diabetic rat model.
    PloS one, 2013, Volume: 8, Issue:10

    Topics: Aldehyde Reductase; Animals; Antioxidants; Biocompatible Materials; Biodegradation, Environmental; B

2013
Luseogliflozin and other sodium-glucose cotransporter 2 inhibitors: no enemy but time?
    Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:4

    Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Sodium-Glucose T

2015
Urocortin ameliorates diabetic nephropathy in obese db/db mice.
    British journal of pharmacology, 2008, Volume: 154, Issue:5

    Topics: Animals; Blood Glucose; Blood Urea Nitrogen; Body Weight; Cell Line; Connective Tissue Growth Factor

2008
Biorhythms of activities of liver and blood dehydrogenases and changes in body weight of the rats feeding normal diet or excess of sugar substitutes.
    Bulletin of experimental biology and medicine, 2007, Volume: 144, Issue:6

    Topics: Animals; Body Weight; Glucosephosphate Dehydrogenase; L-Iditol 2-Dehydrogenase; L-Lactate Dehydrogen

2007
Polyol pathway mediates enhanced degradation of extracellular matrix via p38 MAPK activation in intervertebral disc of diabetic rats.
    Connective tissue research, 2013, Volume: 54, Issue:2

    Topics: ADAM Proteins; Aggrecans; Aldehyde Reductase; Animals; Blood Glucose; Blotting, Western; Body Weight

2013
CHANGES IN WEIGHT AND ADENOSINE TRIPHOSPHATE CONTENT IN THE LENS OF THE XYLOSE-FED RAT.
    Experimental eye research, 1963, Volume: 2

    Topics: Adenosine Triphosphate; Alcohols; Body Weight; Diet; Lens, Crystalline; Metabolism; Rats; Research;

1963
THE DISTRIBUTION OF PARENTERAL IRON HAEMATINICS IN NONPREGNANT, PREGNANT AND LACTATING RATS.
    British journal of pharmacology and chemotherapy, 1964, Volume: 22

    Topics: Animals; Blood Volume Determination; Body Weight; Breast Feeding; Citric Acid; Drug Combinations; Er

1964
THE EFFECTS OF PENICILLIN, DL-PENICILLAMINE, AND D-SORBITOL ON ERYTHROCYTE TRANSKETOLASE ACTIVITY IN THIAMINE-DEFICIENT RATS.
    Toxicology and applied pharmacology, 1964, Volume: 6

    Topics: Body Weight; Erythrocytes; International Cooperation; Metabolism; Penicillamine; Penicillins; Pharma

1964
TOXICITY TESTING OF FAT EMULSIONS FOR INTRAVENOUS ADMINISTRATION.
    The American journal of clinical nutrition, 1965, Volume: 16

    Topics: Administration, Intravenous; Animals; Blood Cell Count; Body Weight; Cottonseed Oil; Egg Yolk; Emuls

1965
A study on the effects to diabetic nephropathy of Hachimi-jio-gan in rats.
    Nephron. Experimental nephrology, 2004, Volume: 97, Issue:2

    Topics: Administration, Oral; Animals; Blood Glucose; Body Weight; Creatinine; Diabetes Mellitus, Experiment

2004
Evaluation of orally active poly(ADP-ribose) polymerase inhibitor in streptozotocin-diabetic rat model of early peripheral neuropathy.
    Diabetologia, 2004, Volume: 47, Issue:4

    Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Diureti

2004
Antihypertensive treatment and renal damage: amlodipine exerts protective effect through the polyol pathway.
    Journal of cardiovascular pharmacology, 2004, Volume: 44, Issue:3

    Topics: Administration, Oral; Amlodipine; Animals; Blood Glucose; Blood Pressure; Body Weight; Collagen Type

2004
Protection from spontaneous hepatocellular damage by N-benzyl-d-glucamine dithiocarbamate in Long-Evans Cinnamon rats, an animal model of Wilson's disease.
    Toxicology and applied pharmacology, 2005, Jan-01, Volume: 202, Issue:1

    Topics: Animals; Body Weight; Chelating Agents; Copper; Disease Models, Animal; Dose-Response Relationship,

2005
Age-related alterations in the biochemical and functional properties of the bladder in type 2 diabetic GK rats.
    Journal of receptor and signal transduction research, 2005, Volume: 25, Issue:3

    Topics: Acetylcholine; Adenosine Triphosphate; Aging; Animals; Body Weight; Carbachol; Diabetes Complication

2005
Attenuation of hypertriglyceridemia-induced pressor effect in rats with fructose-induced insulin resistance.
    The Chinese journal of physiology, 2007, Feb-28, Volume: 50, Issue:1

    Topics: Animals; Blood Glucose; Blood Pressure; Body Weight; Diet; Drug Combinations; Fructose; Heart Rate;

2007
Effect of various sugars and sugar substitutes on dental caries in hamsters and rats.
    The Journal of nutrition, 1967, Volume: 93, Issue:1

    Topics: Animals; Body Weight; Cariogenic Agents; Cricetinae; Dental Caries; Dental Plaque; Dietary Carbohydr

1967
[Effect of sorbinicate on blood proteins and platelet aggregation in patients with coronary disease].
    La Clinica terapeutica, 1984, Jul-31, Volume: 110, Issue:2

    Topics: Adult; Body Weight; Humans; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Myocardial Infarc

1984
Dental effects of xylitol compared with other carbohydrates and polyols in the diet of laboratory rats.
    Archives of oral biology, 1983, Volume: 28, Issue:8

    Topics: Animals; Body Weight; Dental Caries; Dental Plaque; Diet, Cariogenic; Dietary Carbohydrates; Female;

1983
[Evolution of postprandial cholesterolemia and triglyceridemia with age in the preruminant calf; the effect of sorbitol ingestion].
    Reproduction, nutrition, developpement, 1983, Volume: 23, Issue:1

    Topics: Aging; Animals; Body Weight; Cattle; Cholesterol; Cholesterol Esters; Feeding Behavior; Free Radical

1983
Transport of myo-inositol into endoneurial preparations of sciatic nerve from normal and streptozotocin-diabetic rats.
    The Biochemical journal, 1983, Mar-15, Volume: 210, Issue:3

    Topics: Adenosine Triphosphate; Animals; Biological Transport, Active; Body Weight; Diabetes Mellitus, Exper

1983
Beneficial effects of low-carbohydrate--high-protein diets in long-term diabetic rats.
    Metabolism: clinical and experimental, 1980, Volume: 29, Issue:5

    Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diet, Diabetic; Dietary Carboh

1980
Effect of dietary carbohydrates and biotin level on cecal size and biotin concentration of growing chickens.
    Poultry science, 1980, Volume: 59, Issue:7

    Topics: Animals; Biotin; Body Weight; Cecum; Chickens; Dextrins; Dietary Carbohydrates; Glucose; Sorbitol; S

1980
Effect of a potent new aldose reductase inhibitor, (5-(3-thienyltetrazol-1-yl)acetic acid (TAT), on diabetic neuropathy in rats.
    Diabetes research and clinical practice, 1995, Volume: 27, Issue:2

    Topics: Aldehyde Reductase; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetic N

1995
Prevention of diabetic vascular dysfunction by guanidines. Inhibition of nitric oxide synthase versus advanced glycation end-product formation.
    Diabetes, 1993, Volume: 42, Issue:2

    Topics: Aldehyde Reductase; Amino Acid Oxidoreductases; Animals; Arginine; Benzothiazoles; Blood Pressure; B

1993
Aldose reductase inhibition restores endothelial cell function in diabetic rabbit aorta.
    Journal of cardiovascular pharmacology, 1993, Volume: 21, Issue:2

    Topics: Acetylcholine; Adenosine Diphosphate; Aldehyde Reductase; Animals; Aorta; Blood Glucose; Body Weight

1993
The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat.
    Diabetologia, 1995, Volume: 38, Issue:4

    Topics: Albuminuria; Aldehyde Reductase; Animals; Antioxidants; Blood Glucose; Body Weight; Butylated Hydrox

1995
Galactosemia produces ARI-preventable nodal changes similar to those of diabetic neuropathy.
    Diabetes research and clinical practice, 1994, Volume: 25, Issue:2

    Topics: Aldehyde Reductase; Animals; Axons; Body Weight; Diabetic Neuropathies; Fructose; Galactitol; Galact

1994
Tolrestat treatment prevents modification of the formalin test model of prolonged pain in hyperglycemic rats.
    Pain, 1994, Volume: 58, Issue:3

    Topics: Aldehyde Reductase; Animals; Behavior, Animal; Body Weight; Diabetes Mellitus, Experimental; Female;

1994
Inhibition of cisplatin toxicity without decreasing antitumor efficacy. Use of a dithiocarbamate.
    Archives of otolaryngology--head & neck surgery, 1994, Volume: 120, Issue:11

    Topics: Animals; Anorexia; Body Weight; Chelating Agents; Cisplatin; Male; Melanoma, Experimental; Mice; Mic

1994
[The Longmire gastrectomy in the animal model: postoperative changes in fat resorption and the hormones cholecystokinin and secretin].
    Langenbecks Archiv fur Chirurgie, 1994, Volume: 379, Issue:5

    Topics: Animals; Body Weight; Cholecystokinin; Dietary Fats; Drug Combinations; Fat Emulsions, Intravenous;

1994
Osmotically-induced nerve taurine depletion and the compatible osmolyte hypothesis in experimental diabetic neuropathy in the rat.
    Diabetologia, 1993, Volume: 36, Issue:7

    Topics: Aldehyde Reductase; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetic N

1993
Protective effect of N-benzyl-D-glucamine dithiocarbamate against renal toxicity in rats during repeated cis-diamminedichloroplatinum administrations.
    Renal failure, 1995, Volume: 17, Issue:5

    Topics: Animals; Blood Urea Nitrogen; Body Weight; Chelating Agents; Cisplatin; Creatinine; Glutathione; Inj

1995
Effects of propionyl-L-carnitine and insulin on the electroretinogram, nerve conduction and nerve blood flow in rats with streptozotocin-induced diabetes.
    Pflugers Archiv : European journal of physiology, 1996, Volume: 431, Issue:4

    Topics: Animals; Blood Glucose; Body Weight; Cardiotonic Agents; Carnitine; Diabetes Mellitus, Experimental;

1996
Interactions between essential fatty acid, prostanoid, polyol pathway and nitric oxide mechanisms in the neurovascular deficit of diabetic rats.
    Diabetologia, 1996, Volume: 39, Issue:2

    Topics: Acetanilides; Aldehyde Reductase; Analysis of Variance; Animals; Arginine; Blood Glucose; Body Weigh

1996
Polyol pathway, 2,3-diphosphoglycerate in erythrocytes and diabetic neuropathy in rats.
    European journal of pharmacology, 1995, Dec-27, Volume: 294, Issue:1

    Topics: 2,3-Diphosphoglycerate; Aldehyde Reductase; Animals; Body Weight; Diabetic Neuropathies; Diphosphogl

1995
Morphophysiologic characterization of peripheral neuropathy in zinc-deficient guinea pigs.
    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 1996, Volume: 213, Issue:1

    Topics: Animals; Blood Glucose; Body Weight; Brachial Plexus; Carbohydrates; Evoked Potentials, Somatosensor

1996
Effect of propionyl-L-carnitine on oscillatory potentials in electroretinogram in streptozotocin-diabetic rats.
    European journal of pharmacology, 1996, Sep-12, Volume: 311, Issue:2-3

    Topics: Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Body Weight;

1996
Effects of a novel potent aldose reductase inhibitor, GP-1447, on aldose reductase activity in vitro and on diabetic neuropathy and cataract formation in rats.
    Japanese journal of pharmacology, 1997, Volume: 73, Issue:2

    Topics: Aldehyde Reductase; Animals; Blood Glucose; Body Weight; Cataract; Diabetes Mellitus, Experimental;

1997
Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats.
    Diabetologia, 1997, Volume: 40, Issue:3

    Topics: Aldehyde Reductase; Analysis of Variance; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Ex

1997
Cataract development induced by repeated oral dosing with FK506 (tacrolimus) in adult rats.
    Toxicology, 1997, Dec-05, Volume: 123, Issue:3

    Topics: Administration, Oral; Aldehyde Reductase; Animals; Blood Glucose; Body Weight; Cataract; Diabetes Me

1997
Electroretinogram in sucrose-fed diabetic rats treated with an aldose reductase inhibitor or an anticoagulant.
    The American journal of physiology, 1997, Volume: 273, Issue:5

    Topics: 2,3-Diphosphoglycerate; Aldehyde Reductase; Animals; Anticoagulants; Blood Glucose; Body Weight; Cil

1997
Amelioration of neurovascular deficits in diabetic rats by a novel aldose reductase inhibitor, GP-1447: minor contribution of nitric oxide.
    Diabetes research and clinical practice, 1998, Volume: 40, Issue:2

    Topics: Aldehyde Reductase; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetic N

1998
Effects of thyroid hormone on the sorbitol pathway in streptozotocin-induced diabetic rats.
    Biochimica et biophysica acta, 1998, Nov-27, Volume: 1425, Issue:3

    Topics: Aldehyde Reductase; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Hyperthyro

1998
Biological evaluation of the nitric oxide-trapping agent, N-methyl-D-glucamine dithiocarbamate-Fe2+, as a probe of nitric oxide activity released from control and diabetic rat endothelium.
    Japanese journal of pharmacology, 1999, Volume: 80, Issue:4

    Topics: Acetylcholine; Animals; Aorta, Thoracic; Blood Glucose; Body Weight; Chelating Agents; Diabetes Mell

1999
Evaluation of alpha(1)-adrenoceptor antagonist on diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2000, Volume: 14, Issue:11

    Topics: Adrenergic alpha-Antagonists; Animals; Antioxidants; Blood Glucose; Blood Pressure; Body Weight; Cre

2000
Effects of 15-month aldose reductase inhibition with fidarestat on the experimental diabetic neuropathy in rats.
    Diabetes research and clinical practice, 2000, Volume: 50, Issue:2

    Topics: Aldehyde Reductase; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetic N

2000
Diabetes-induced biochemical changes in rat lens: attenuation of cataractogenesis by pyruvate.
    Diabetes, obesity & metabolism, 2000, Volume: 2, Issue:3

    Topics: Adenosine Triphosphate; Animals; Body Weight; Cataract; Crystallins; Diabetes Mellitus, Experimental

2000
Pharmacological properties of fidarestat, a potent aldose reductase inhibitor, clarified by using sorbitol in human and rat erythrocytes.
    Pharmacology, 2001, Volume: 62, Issue:4

    Topics: Age Factors; Aldehyde Reductase; Animals; Blood Glucose; Body Weight; Diabetes Mellitus; Diabetes Me

2001
Effect of M40403 treatment of diabetic rats on endoneurial blood flow, motor nerve conduction velocity and vascular function of epineurial arterioles of the sciatic nerve.
    British journal of pharmacology, 2001, Volume: 134, Issue:1

    Topics: Acetylcholine; Animals; Blood Glucose; Blood Vessels; Body Weight; Diabetes Mellitus, Experimental;

2001
Potentiation of carbon tetrachloride hepatotoxicity in rats by pretreatment with polychlorinated biphenyls.
    Toxicology, 1975, Volume: 5, Issue:1

    Topics: Alanine Transaminase; Alcohol Oxidoreductases; Animals; Aspartate Aminotransferases; Body Weight; Ca

1975
Human exocrine pancreatic response with different types of secretin. Influence of sex, age, and previous intraduodenal sorbitol infusion.
    The American journal of gastroenterology, 1978, Volume: 69, Issue:2

    Topics: Adult; Age Factors; Aged; Amylases; Bicarbonates; Body Weight; Female; Humans; Male; Middle Aged; Pa

1978
Effect of a prostaglandin I2 derivative (iloprost) on peripheral neuropathy of diabetic rats.
    Diabetes research and clinical practice, 1992, Volume: 18, Issue:2

    Topics: Animals; Blood Glucose; Body Weight; Cyclic AMP; Diabetes Mellitus, Experimental; Diabetic Neuropath

1992
Effects of a new aldose reductase inhibitor, (2S, 4S)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazolidine]-2-ca rboxamid e (SNK-860), on the slowing of motor nerve conduction velocity and metabolic abnormalities in the peripheral nerve in acute streptozo
    Metabolism: clinical and experimental, 1992, Volume: 41, Issue:10

    Topics: Aldehyde Reductase; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetic N

1992
Amelioration of dermal lesions in streptozotocin-induced diabetic rats by aminoguanidine.
    Diabetes research (Edinburgh, Scotland), 1992, Volume: 20, Issue:4

    Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Electrophoresis, Polyacrylamid

1992
Effects on rat renal osmolytes of extended treatment with an aldose reductase inhibitor.
    Comparative biochemistry and physiology. C, Comparative pharmacology and toxicology, 1992, Volume: 103, Issue:3

    Topics: Aldehyde Reductase; Animals; Betaine; Body Weight; Imidazoles; Imidazolidines; Kidney; Male; Osmolar

1992
Dissociation between biochemical and functional effects of the aldose reductase inhibitor, ponalrestat, on peripheral nerve in diabetic rats.
    British journal of pharmacology, 1992, Volume: 107, Issue:4

    Topics: Aldehyde Reductase; Animals; Blood Glucose; Body Weight; Diabetic Neuropathies; Fructose; Hypoglycem

1992
Renal sorbitol, myo-inositol and glycerophosphorylcholine in streptozotocin-diabetic rats.
    European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies, 1992, Volume: 30, Issue:10

    Topics: Animals; Blood Glucose; Blood Proteins; Body Weight; Creatinine; Diabetes Mellitus, Experimental; Di

1992
Effect of vitamin C on sorbitol in the lens of guinea-pigs made diabetic with streptozotocin.
    The British journal of nutrition, 1992, Volume: 67, Issue:3

    Topics: Adenosine Triphosphate; Animals; Aqueous Humor; Ascorbic Acid; Ascorbic Acid Deficiency; Blood Gluco

1992
Distribution and excretion of cadmium and nickel after simultaneous exposure and the effect of N-benzyl-D-glucamine dithiocarbamate on their biliary and urinary excretion.
    Journal of toxicology and environmental health, 1992, Volume: 35, Issue:4

    Topics: Administration, Oral; Animals; Bile; Body Weight; Brain; Cadmium; Chelating Agents; Drinking; Drug I

1992
Amelioration of nerve Na(+)-K(+)-ATPase activity independently of myo-inositol level by PGE1 analogue OP-1206.alpha-CD in streptozocin-induced diabetic rats.
    Diabetes, 1991, Volume: 40, Issue:6

    Topics: Alprostadil; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Inositol; Male; M

1991
Aldose reductase inhibition with imirestat-effects on impulse conduction and insulin-stimulation of Na+/K(+)-adenosine triphosphatase activity in sciatic nerves of streptozotocin-diabetic rats.
    Diabetologia, 1991, Volume: 34, Issue:6

    Topics: Action Potentials; Aldehyde Reductase; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Exper

1991
Adenosine triphosphatase activity in sciatic nerve tissue of streptozocin-induced diabetic rats with and without high dietary sucrose: effect of aldose reductase inhibitors.
    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 1991, Volume: 197, Issue:2

    Topics: Aldehyde Reductase; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Dietary Ca

1991
Glutathione and related indices in rat lenses, liver and red cells during riboflavin deficiency and its correction.
    Experimental eye research, 1991, Volume: 53, Issue:1

    Topics: Animals; Body Weight; Erythrocytes; Female; Glucose; Glutathione; Glutathione Reductase; Lens, Cryst

1991
Effect of cadmium-mobilizing dithiocarbamates on essential trace metal metabolism in rats.
    Bulletin of environmental contamination and toxicology, 1991, Volume: 47, Issue:1

    Topics: Animals; Body Weight; Cadmium; Chelating Agents; Female; Kidney; Liver; Rats; Sorbitol; Spin Labels;

1991
Monoaminoguanidine prevents sorbitol accumulation, nonenzymatic protein glycosylation and development of kidney lesions in diabetic rats.
    Experientia, 1991, Mar-15, Volume: 47, Issue:3

    Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glycos

1991
Protection against cis-diamminedichloroplatinum-induced nephrotoxicity in rats by N-benzyl-D-glucamine dithiocarbamate.
    Toxicology, 1991, Mar-25, Volume: 67, Issue:1

    Topics: Animals; Aspartate Aminotransferases; Blood Urea Nitrogen; Body Weight; Carcinoma 256, Walker; Cispl

1991
In vivo activities of aldose reductase inhibitors having a 1-(arylsulfonyl)hydantoin structure.
    Biochemical pharmacology, 1990, Jul-15, Volume: 40, Issue:2

    Topics: Aldehyde Reductase; Animals; Body Weight; Cataract; Diabetes Mellitus, Experimental; Galactosemias;

1990
The significance of nerve sugar levels for the peripheral nerve impairment of spontaneously diabetic GK (Goto-Kakizaki) rats.
    Diabetes research (Edinburgh, Scotland), 1990, Volume: 14, Issue:1

    Topics: Aging; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Fructose; Glucose; Inos

1990
Copper deficiency in pregnancy: effect on maternal and fetal polyol metabolites.
    Metabolism: clinical and experimental, 1990, Volume: 39, Issue:5

    Topics: Animals; Blood Glucose; Body Weight; Carbohydrate Metabolism; Carbohydrates; Catecholamines; Copper;

1990
Reversal of deficits in axonal transport and nerve conduction velocity by treatment of streptozotocin-diabetic rats with myo-inositol.
    Experimental neurology, 1985, Volume: 89, Issue:2

    Topics: Administration, Oral; Animals; Axonal Transport; Blood Glucose; Body Weight; Diabetes Mellitus, Expe

1985
Studies on peripheral nerve and lens in long-term experimental diabetes: effects of the aldose reductase inhibitor statil.
    Metabolism: clinical and experimental, 1988, Volume: 37, Issue:5

    Topics: Aldehyde Reductase; Animals; Axonal Transport; Body Weight; Carbohydrates; Choline O-Acetyltransfera

1988
Sorbinil suppresses glomerular prostaglandin production in the streptozotocin diabetic rat.
    Metabolism: clinical and experimental, 1989, Volume: 38, Issue:7

    Topics: 6-Ketoprostaglandin F1 alpha; Aldehyde Reductase; Animals; Blood Glucose; Body Weight; Diabetes Mell

1989
Carbon tetrachloride and the sorbitol pathway in the diabetic mouse.
    Comparative biochemistry and physiology. B, Comparative biochemistry, 1989, Volume: 94, Issue:1

    Topics: Animals; Blood Glucose; Body Weight; Carbon Tetrachloride; Diabetes Mellitus, Experimental; Fructose

1989
Chemotherapy of experimental visceral leishmaniasis in the opossum.
    The Journal of parasitology, 1989, Volume: 75, Issue:1

    Topics: Aminoquinolines; Animals; Antiprotozoal Agents; Body Weight; Female; Leishmaniasis, Visceral; Liver;

1989
The effect of aldose reductase inhibitor Statil (ICI 128436) on the glucose over-utilization in kidney of diabetic rats.
    Biochemical pharmacology, 1988, Sep-01, Volume: 37, Issue:17

    Topics: Animals; Body Weight; Diabetes Mellitus, Experimental; Glucose; Glucuronates; Kidney; Lactates; Orga

1988
Prevention of neural myoinositol depletion in diabetic rats by aldose reductase inhibition with tolrestat.
    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 1986, Volume: 182, Issue:4

    Topics: Aldehyde Reductase; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Glucose; I

1986
Increased vascular permeability in spontaneously diabetic BB/W rats and in rats with mild versus severe streptozocin-induced diabetes. Prevention by aldose reductase inhibitors and castration.
    Diabetes, 1987, Volume: 36, Issue:7

    Topics: Aldehyde Reductase; Animals; Aorta; Blood Glucose; Body Weight; Capillary Permeability; Castration;

1987
Specific radioimmunoassay of glucitol-lysine--application to lens proteins in streptozotocin-diabetic rats.
    Diabetologia, 1988, Volume: 31, Issue:4

    Topics: Animals; Blood Glucose; Body Weight; Crystallins; Diabetes Mellitus, Experimental; Lysine; Male; Rad

1988
Methylcobalamin improves nerve conduction in streptozotocin-diabetic rats without affecting sorbitol and myo-inositol contents of sciatic nerve.
    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 1988, Volume: 20, Issue:11

    Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Inositol; Male; Neural Conduct

1988
N-alkyl-N-dithiocarboxy-D-glucamine analogs as cadmium antagonists: synthesis and evaluation of the n-propyl, n-butyl, and n-amyl derivatives.
    Archives of toxicology, 1988, Volume: 62, Issue:6

    Topics: Animals; Body Weight; Cadmium; Chemical Phenomena; Chemistry; Chemistry, Physical; Dose-Response Rel

1988
Diabetes affects sorbitol and myo-inositol levels of neuroectodermal tissue during embryogenesis in rat.
    Diabetes, 1988, Volume: 37, Issue:7

    Topics: Adenosine Diphosphate; Adenosine Triphosphate; Animals; Body Weight; Creatine; Diabetes Mellitus, Ex

1988
Organic aciduria in rats fed high amounts of xylitol or sorbitol.
    Toxicology and applied pharmacology, 1987, Sep-15, Volume: 90, Issue:2

    Topics: Animals; Body Weight; Citrates; Citric Acid; Cytoplasm; Gas Chromatography-Mass Spectrometry; Hydrog

1987
The long-term effect of dietary administration of refined sugars and sugar alcohols on plasma biochemistry, urine biochemistry and tissue histology in mice given a limited degree of dietary self-selection.
    Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 1986, Volume: 24, Issue:5

    Topics: Animals; Blood Chemical Analysis; Body Weight; Creatinine; Dietary Carbohydrates; Eating; Energy Int

1986
Three-generation reproduction study of rats ingesting up to 10% sorbitol in the diet--and a brief review of the toxicological status of sorbitol.
    Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 1986, Volume: 24, Issue:3

    Topics: Adrenal Medulla; Animals; Body Weight; Calcium; Diet; Eating; Female; Fertility; Liver; Male; Organ

1986
Addition of sorbitol to a milk substitute for veal calves. I. Effects on health, growth and feed conversion.
    Reproduction, nutrition, developpement, 1985, Volume: 25, Issue:2

    Topics: Animal Nutritional Physiological Phenomena; Animals; Body Weight; Cattle; Dietary Fats; Dietary Prot

1985
[Effect of various nutritive intravenous perfusions on the oral intake in the rat].
    Comptes rendus hebdomadaires des seances de l'Academie des sciences. Serie D: Sciences naturelles, 1973, Aug-06, Volume: 277, Issue:6

    Topics: Administration, Oral; Amino Acids; Animal Feed; Animal Nutritional Physiological Phenomena; Animals;

1973
Sorbitol in total parenteral nutrition in pediatric patients.
    Helvetica paediatrica acta, 1973, Volume: 28, Issue:6

    Topics: Acute Disease; Body Weight; Child; Child, Preschool; Chromatography, Gas; Dietary Carbohydrates; Diu

1973
The effects of intravenous protein--calorie supplementation on the tissue composition of postoperative body weight loss.
    Postgraduate medical journal, 1974, Volume: 50, Issue:585

    Topics: Adult; Amino Acids; Body Weight; Energy Metabolism; Evaluation Studies as Topic; Glucose; Humans; Ma

1974
Metabolism of sorbitol modified by ethanol in rats fed with a choline-deficient or choline-supplemented low-protein high-fat diet.
    Life sciences. Pt. 2: Biochemistry, general and molecular biology, 1971, Aug-22, Volume: 10, Issue:16

    Topics: Animals; Body Weight; Choline; Cytoplasm; Depression, Chemical; Dietary Fats; Dietary Proteins; Etha

1971
[Metabolic effects of various carbohydrates and their significance for infusion therapy].
    Zeitschrift fur Ernahrungswissenschaft. Journal of nutritional sciences. Supplementa, 1973, Volume: 15

    Topics: Alanine Transaminase; Animals; Bilirubin; Blood Glucose; Body Weight; Carbohydrate Metabolism; Fruct

1973
The effect of environmental temperature and nutritional intake on the metabolic response to abdominal surgery.
    The British journal of surgery, 1972, Volume: 59, Issue:2

    Topics: Abdomen; Adult; Body Weight; Caseins; Creatinine; Diet; Energy Metabolism; Environment; Gastrectomy;

1972
Safety of nuts heat-processed in molten hexitols.
    Journal of the American Oil Chemists' Society, 1973, Volume: 50, Issue:9

    Topics: Animal Nutritional Physiological Phenomena; Animals; Arachis; Body Weight; Cholesterol; Cooking; Eva

1973
Rates of elimination of sorbitol and ethanol in the choline-deficient fatty liver.
    Scandinavian journal of clinical and laboratory investigation, 1971, Volume: 28, Issue:3

    Topics: Alcohol Oxidoreductases; Animals; Body Weight; Choline Deficiency; Diet; Dietary Fats; Ethanol; Fatt

1971
[Use of sorbitol in edema resistant to diuretic therapy].
    Vnitrni lekarstvi, 1971, Volume: 17, Issue:11

    Topics: Body Weight; Diarrhea; Diuresis; Edema; Female; Humans; Osmolar Concentration; Sorbitol; Water-Elect

1971
Inhibition of sorbitol oxidation by ethanol in intact rats pretreated with triiodothyronine or propyl thiouracil.
    Biochemical pharmacology, 1970, Volume: 19, Issue:2

    Topics: Animals; Body Weight; Ethanol; Hyperthyroidism; Hypothyroidism; Liver; Male; Organ Size; Oxidation-R

1970
Liver alcohol and sorbitol dehydrogenase activities in hypo- and hyperthyroid rats.
    Biochemical pharmacology, 1970, Volume: 19, Issue:6

    Topics: Alcohol Drinking; Alcohol Oxidoreductases; Animals; Body Weight; Depression, Chemical; Diet; Ethanol

1970
[Vitamin B1 metabolism and sorbitol].
    Internationale Zeitschrift fur Vitaminforschung. International journal of vitamin research. Journal international de vitaminologie, 1967, Volume: 37, Issue:4

    Topics: Animals; Body Weight; Bradycardia; Furans; Heart Rate; Liver Glycogen; Pyrimidines; Rats; Sorbitol;

1967
Effects of infusion rate and osmolarity on volumogenic diarrhea.
    Gastroenterology, 1969, Volume: 57, Issue:1

    Topics: Animals; Body Weight; Diarrhea; Dogs; Hypertonic Solutions; Isotonic Solutions; Osmolar Concentratio

1969